Scleroderma Diagnostics and Therapeutics Market Scleroderma Diagnostics and Therapeutics Market -

Scleroderma Diagnostics and Therapeutics Market - Global
Industry Analysis, Size, Share, Growth, Trends, and Forecast
2016 – 2024
Global Scleroderma Diagnostics and Therapeutics Market: Overview
Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words
“sklerosis,” which means hardness, and “derma,” meaning skin. Thus, scleroderma literally translates
to “hard skin.” Scleroderma is a group of diseases that involves the abnormal growth of connective
tissue, which supports the skin and internal organs. In some forms of scleroderma, the extent of the
abnormality of the disease is limited to hard, tight skin. In certain other forms, however, the
predicament is worse, where the impact goes much deeper, affecting blood vessels and internal
organs, such as the heart, lungs, and kidneys. Scleroderma has no known cure and is a chronic
condition, in which patients are affected for life. Localized scleroderma patients, however, with mild
symptoms, often see the skin patches disappear on their own in a few years post-onset.
This 176 page report gives readers a comprehensive overview of the Scleroderma Diagnostics and
Therapeutics market Browse through 26 data tables and 69 figures to unlock the hidden opportunities
in this market.
http://www.transparencymarketresearch.com/scleroderma-diagnostics-therapeutics.html
Global Scleroderma Diagnostics and Therapeutics Market: Scope of the Report
This report on the global scleroderma diagnostics and therapeutics market analyzes the current and
future prospects of the market. The markets of diagnostics and therapeutics are independently
analyzed as two separate markets within the report. The market for scleroderma therapeutics is
segmented based on drug class, indication and region, while the market for scleroderma diagnostics
is segmented on the basis of test type and region. The report comprises an elaborate executive
summary, including a market snapshot that provides overall information of various segments and sub-
segments. The research is a combination of primary and secondary research.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and
opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn
for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from
2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related
factors such as new drug launches, drugs in the pipeline, industry-institute collaborations in research
for finding a pertinent cure, and historical year-on-year growth have been taken into consideration
while estimating the market size. Growth rates for each segment within the global scleroderma
diagnostics and therapeutics market have been determined after a thorough analysis of past trends,
demographics, future trends, technological developments, clinical trials, and regulatory requirements.